Edit
Celltrion Healthcare Co.,Ltd.
http://www.celltrionhealthcare.com/Last activity: 15.02.2024
Active
Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines through an extensive global network that spans more than 120 different countries. Celltrion Healthcare provides REMSIMA, the world's first biosimilar monoclonal antibody (mAb) approved by the European Medicines Agency (EMA) for the treatment of autoimmune disease, and innovative biopharmaceutical medications to help increase patient access to advanced therapies around the world.
For additional information on our guidelines, please visit
https://bit.ly/3BnYi2c
For additional information on our guidelines, please visit
https://bit.ly/3BnYi2c
Location: South Korea, Incheon
Employees: 51-200
Phone: +82 32-850-6400
Founded date: 1999
Investors 2
| Date | Name | Website |
| - | One Equity... | oneequity.... |
| - | Temasek Ho... | temasek.co... |
Mentions in press and media 5
| Date | Title | Description |
| 15.02.2024 | Greg Belinfanti Appointed President Of One Equity Partner; Dick Cashin Continues Full-Time Role As Chairman | One Equity Partners (“OEP”), a middle-market private equity firm, today announced that Greg Belinfanti has been named President of the firm. Belinfanti has been with OEP for more than 17 years and an important member of OEP’s Investment ... |
| 15.11.2021 | Celltrion Receives CHMP Positive Opinion for regdanvimab (CT-P59) as One of the First Monoclonal Antibodies for COVID-19 by the CHMP | INCHEON, Korea - Celltrion Group announced that the European Medicine's Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive scientific opinion recommending marketing authorisation for regdanvimab (CT-P59),... |
| 01.04.2021 | CELLTRION, INC. Celltrion : Healthcare receives positive CHMP opinion for subcutaneous formulation of infliximab, Remsima SC, for direct use of subcutaneous therapy without IV loading in adults with ... | INCHEON, South Korea - Celltrion Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended Remsima SC for direct use of subcutaneous therapy without IV l... |
| 26.03.2021 | EMA: Ongoing study data of Celltrion’s mAb enough to allow its use in some Covid-19 patients | The European Medicines Agency added another monoclonal antibody to the continent’s Covid-19 therapeutics arsenal on Friday, concluding that Celltrion’s regdanvimab can be used as a treatment for adults with Covid-1... |
| 07.06.2017 | Term Sheet — Wednesday, June 7 | 500 Hello, it’s Fortune 500 day! The 2017 list is live here. For 63 years, this list has ranked the largest companies in the U.S. by revenue. Paid Content You can't secure what you can't see From ExtraHop KKR got rather dramatically knocked... |